Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zymeworks ( (ZYME) ) has shared an update.
On August 7, 2025, Zymeworks Inc. reported its second quarter financial results, highlighting a revenue of $48.7 million and a cash reserve of $333.4 million as of June 30, 2025. The company announced the FDA clearance of an IND application for ZW251, with first-in-human studies planned for 2025, and noted international approvals for zanidatamab in biliary tract cancer. These developments, along with strategic partnerships, are expected to enhance Zymeworks’ long-term business strategy and financial stability.
The most recent analyst rating on (ZYME) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks faces notable financial challenges with negative profitability and cash flow issues, significantly impacting its stock score. However, positive sentiment from the earnings call, driven by revenue growth and strategic partnerships, offers some optimism. The technical analysis and valuation scores are moderate, reflecting a mixed short-term outlook.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company based in Vancouver, British Columbia, focusing on developing novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune diseases.
Average Trading Volume: 458,193
Technical Sentiment Signal: Hold
Current Market Cap: $881M
For detailed information about ZYME stock, go to TipRanks’ Stock Analysis page.